Standing Order
Novo Nordisk A/S

Dashboard

Novo Nordisk A/S

NVONYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$163B
Price$48.7752w $35.29 – $81.05
Conviction4/ 5
Revenue (TTM)$50.0B
Revenue growth YoY+8.1%
P/E (trailing)8.8
Gross margin81.8%
Operating margin45.3%
Net margin37.2%
52w price change-33.0%
Next earningsAug 5, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Jul 24
    OtherClinicalTrials.gov

    Phase 3 trial NCT07011667 for CagriSema in long-term obesity weight loss updated to ACTIVE_NOT_RECRUITING.

  • Jul 23
    Trial initiationClinicalTrials.gov

    Phase 3 CLEOPATTRA trial (NCT07207811) initiated for Coramitug in ATTR amyloidosis heart failure; recruiting status per 2026-07-23 update.

  • Jul 22
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07720271 (Zenagamtide tablets, excess body weight) status NOT_YET_RECRUITING.

  • Jul 22
    Trial readoutClinicalTrials.gov

    Phase 2 trial NCT05405114 of NDec in sickle cell disease completed (status update 2026-07-22).

  • Jul 21
    Trial initiationClinicalTrials.gov

    Novo Nordisk initiates Phase 1 trial NCT07225816 (recruiting) examining effects of fasting duration and temporary GLP-1 pause on gastric retention for liraglutide and semaglutide users.

  • Jul 21
    Trial initiationClinicalTrials.gov

    Novo Nordisk updates NCT05503927 Wegovy pregnancy safety study status to ENROLLING_BY_INVITATION.

  • Jul 21
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07668401 (Zenagamtide, Asia weight loss) status NOT_YET_RECRUITING as of 2026-07-21.

  • Jul 21
    OtherSEC

    Novo Nordisk filed Form 6-K foreign issuer report.

  • Jul 20
    Trial initiationClinicalTrials.gov

    Novo Nordisk starts enrolling database linkage study NCT07713901 evaluating medullary thyroid carcinoma risk.

  • Jul 20
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07270731 initiated for NNC9733-0001 in healthy and T2D participants

  • Jul 17
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 1 trial NCT07710768 (UBT251 drug-interaction study) status updated to not yet recruiting.

  • Jul 17
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07710729 for UBT251 (interaction with birth control and gastric emptying) posted as not yet recruiting.

  • Jul 17
    Trial initiationClinicalTrials.gov

    Novo Nordisk initiates Phase 3 trial NCT07253285 evaluating Cagrilintide and CagriSema in children and adolescents with excess body weight; status recruiting.

  • Jul 17
    Trial readoutClinicalTrials.gov

    Phase 3 REDEFINE 3 trial (NCT05669755) of CagriSema in cardiovascular disease updated to ACTIVE_NOT_RECRUITING status.

  • Jul 17
    OtherClinicalTrials.gov

    Phase 3 trial NCT05567796 (CagriSema, excess body weight) status updated to ACTIVE_NOT_RECRUITING on 2026-07-17.

  • Jul 17
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT06534411 of CagriSema vs tirzepatide in T2D completed

  • Jul 15
    Trial initiationClinicalTrials.gov

    Novo Nordisk initiates Phase 3 trial NCT07567001 of NNC0487-0111 vs placebo in heart failure with obesity; status recruiting.

  • Jul 14
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 2 trial NCT07668388 (UBT251, Type 2 diabetes) status updated to RECRUITING

  • Jul 13
    OtherSEC

    Novo Nordisk filed Form 6-K with SEC on 2026-07-13.

  • Jul 13
    Trial initiationClinicalTrials.gov

    Phase 3 AMAZE 4 trial (NCT07571109) of NNC0487-0111 initiated for obesity with OSA; status recruiting.

Not financial advice — research and opinion only. Disclosures